Stock AnalizSotera Health Co SHC
Misc Health and Biotechnology Services · IPO 2020 · data as of November 13, 2026
Sotera Health Co (SHC) is a healthcare company listed in the US with a market value of about $4.7B. In the twelve months to September 30, 2026 it had revenue of $1.2B and net income of $173M, a net margin of 14.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a P/E of 27.7, a price to free cash flow of 35.0, 5-year revenue growth of 7% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Positive free cash flow
- Interest covered more than 5 times
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.1B | $1.0B | $1.0B | $931M | $818M | $778M |
| Net income | $173M | $78M | $44M | $51M | -$234M | $117M | -$39M | -$21M |
| Free cash flow | $135M | $149M | $45M | -$363M | $96M | $179M | $67M | $92M |
| EPS (diluted) | $0.60 | $0.27 | $0.16 | $0.18 | $-0.83 | $0.41 | $-0.16 | $-0.09 |
| Net margin | 14.1% | 6.7% | 4.0% | 4.9% | -23.3% | 12.6% | -4.7% | -2.7% |
| ROIC | — | 2.8% | 8.8% | 8.1% | 10.3% | 7.2% | 8.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $21.44, 29% above the current price; targets range from $15.00 to $25.00; the consensus rating is “Buy”; expected EPS is $0.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Sotera Health Co’s P/E ratio?
About 27.7, based on the last twelve months of diluted earnings per share (forward P/E about 16.7).
Is Sotera Health Co stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sotera Health Co pay a dividend?
Not currently.
Is Sotera Health Co a good stock to buy?
We do not give buy or sell advice. Sotera Health Co scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.